



## **ASX Announcement 21 February 2019**

### **Elixinol Global FY2018 results conference call**

**Elixinol Global Limited (EXL or the Company) (ASX:EXL; OTCQX:ELLXF)**, a global company operating in the industrial hemp, dietary supplements and emerging medicinal cannabis sectors, is pleased to invite investors to participate in the FY2018 results presentation by Chief Executive Officer, Paul Benhaim and Chief Financial Officer, Ron Dufficy, on Tuesday 26 February at 11:00 am (AEST / Sydney time).

During the call, Paul Benhaim and Ron Dufficy will present the Company's FY2018 results, followed by a Q&A session.

**Date and time**                      Tuesday 26 February at 11:00 am am (AEST / Sydney time)

#### **Dial-in details**

Australia	1800 558 698
United Kingdom	0800 051 8245
United States	1 877 642 9125
Canada	1855 8811 339
Hong Kong	800 966 806
Singapore	800 101 2785

**Conference ID**                      788412

#### **Investor relations and media please contact:**

##### **Australia**

Glen Zurcher  
Account Director, IR Department  
[IR@elixinolglobal.com](mailto:IR@elixinolglobal.com)  
+61 420 249 299

##### **United States of America**

Cody Slach  
Managing Director, Liolios Group Inc  
[USIR@elixinolglobal.com](mailto:USIR@elixinolglobal.com)  
+1 949 574 3860

#### **About Elixinol Global**

Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp



food and wellness products, as well as cultivation and manufacture of medicinal cannabis products. EXL's businesses include:

- **Elixinol LLC (“Elixinol”)**, founded in 2014, is a manufacturer and global distributor of hemp dietary supplement and skincare products, with operations based out of Colorado, USA.
- **Hemp Foods Australia**, founded in 1999, is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products.
- **Nunyara Pharma Pty Ltd (“Nunyara”)**, formerly known as Elixinol Australia, was founded in 2014 to participate in the emerging Australian medicinal cannabis market and submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018. These applications are currently pending approval.

See more at [www.elixinolglobal.com](http://www.elixinolglobal.com)